Pompidou report: a time for negotiation
This article was originally published in Clinica
Now is not the time to comment on the draft Pompidou report on the draft IVD-MD Directive, Maurizio Suppo, director of the European Diagnostic Manufacturers Association, has stated. The draft report presented to the European Parliament's Committee on Economic and Monetary Affairs and Industrial Policy (EMEA), reflects many of the views of the French Medicines Agency (see Clinica No 683, p 5), which are not shared by the IVD industry.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.